Is Novo Nordisk Stock a Buy?
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?
There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes various chronic diseases and conditions, including type 2 diabetes. An estimated 830 million people have diabetes, with type 2 being the most common.
Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by slowing digestion and reducing appetite. Researchers believe the GLP-1 agonist market could triple over the next decade to over $150 billion.
Should investors buy Novo Nordisk stock? Here is what to know.
